SI3328867T1 - Kristalna oblika proste baze lorlatiniba - Google Patents

Kristalna oblika proste baze lorlatiniba

Info

Publication number
SI3328867T1
SI3328867T1 SI201631027T SI201631027T SI3328867T1 SI 3328867 T1 SI3328867 T1 SI 3328867T1 SI 201631027 T SI201631027 T SI 201631027T SI 201631027 T SI201631027 T SI 201631027T SI 3328867 T1 SI3328867 T1 SI 3328867T1
Authority
SI
Slovenia
Prior art keywords
free base
crystalline form
lorlatinib free
lorlatinib
crystalline
Prior art date
Application number
SI201631027T
Other languages
English (en)
Inventor
Melissa J. Birch
Klimentina Dimitrova Pencheva
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SI3328867T1 publication Critical patent/SI3328867T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65Raman scattering
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/087Structure determination of a chemical compound, e.g. of a biomolecule such as a protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI201631027T 2015-07-31 2016-07-27 Kristalna oblika proste baze lorlatiniba SI3328867T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562199418P 2015-07-31 2015-07-31
US201662352349P 2016-06-20 2016-06-20
PCT/IB2016/054483 WO2017021823A1 (en) 2015-07-31 2016-07-27 Crystalline form of lorlatinib free base
EP16751665.7A EP3328867B9 (en) 2015-07-31 2016-07-27 Crystalline form of lorlatinib free base

Publications (1)

Publication Number Publication Date
SI3328867T1 true SI3328867T1 (sl) 2021-04-30

Family

ID=56686850

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201631780T SI3798222T1 (sl) 2015-07-31 2016-07-27 Kristalna oblika proste baze lorlatiniba
SI201631027T SI3328867T1 (sl) 2015-07-31 2016-07-27 Kristalna oblika proste baze lorlatiniba

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201631780T SI3798222T1 (sl) 2015-07-31 2016-07-27 Kristalna oblika proste baze lorlatiniba

Country Status (22)

Country Link
US (2) US10420749B2 (sl)
EP (2) EP3328867B9 (sl)
JP (1) JP6218253B2 (sl)
KR (1) KR102088188B1 (sl)
CN (3) CN116063322A (sl)
AU (1) AU2016304420B2 (sl)
BR (1) BR112017028604A2 (sl)
CA (1) CA2937257C (sl)
CY (1) CY1123689T1 (sl)
DK (2) DK3328867T3 (sl)
ES (2) ES2842302T3 (sl)
FI (1) FI3798222T3 (sl)
HK (1) HK1252845A1 (sl)
HU (2) HUE052790T2 (sl)
MX (2) MX2021002220A (sl)
PL (2) PL3328867T3 (sl)
PT (2) PT3328867T (sl)
RU (1) RU2018101363A (sl)
SG (1) SG10201913200XA (sl)
SI (2) SI3798222T1 (sl)
TW (1) TWI616449B (sl)
WO (1) WO2017021823A1 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049383A1 (en) 2015-09-24 2017-03-30 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
EP3440086B1 (en) 2016-04-08 2020-08-12 Pfizer Inc. Crystalline forms of lorlatinib maleate
JP2020524701A (ja) * 2017-06-22 2020-08-20 サイクルニウム ファーマ インコーポレイテッド ピリジン含有大環状化合物ライブラリーならびにその製造および使用方法
SG11202002445SA (en) 2017-10-10 2020-04-29 Pfizer Crystalline form of lorlatinib free base hydrate
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
US20210163498A1 (en) 2018-04-23 2021-06-03 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
CN113260617A (zh) * 2019-01-17 2021-08-13 辉瑞公司 Cdk抑制剂的结晶形式
EP3999514A1 (en) * 2019-07-18 2022-05-25 Pliva Hrvatska D.O.O. Crystalline lorlatinib : fumaric acid and solid state form thereof
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
CN110530998A (zh) * 2019-09-16 2019-12-03 山东省药学科学院 一种劳拉替尼及含劳拉替尼的制剂中有关物质的检测方法
WO2021069571A1 (en) 2019-10-10 2021-04-15 Sandoz Ag Polymorph of lorlatinib
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
CN103476770B (zh) * 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
DK2822953T5 (en) 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
CA2916605C (en) * 2013-06-28 2018-04-24 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
EP3440086B1 (en) 2016-04-08 2020-08-12 Pfizer Inc. Crystalline forms of lorlatinib maleate
SG11202002445SA (en) 2017-10-10 2020-04-29 Pfizer Crystalline form of lorlatinib free base hydrate

Also Published As

Publication number Publication date
HUE052790T2 (hu) 2021-05-28
KR102088188B1 (ko) 2020-03-12
AU2016304420A1 (en) 2018-02-01
CA2937257C (en) 2022-06-14
US20190365712A1 (en) 2019-12-05
BR112017028604A2 (pt) 2018-09-04
PT3328867T (pt) 2021-01-13
CN107849060A (zh) 2018-03-27
MX2018001324A (es) 2018-04-30
FI3798222T3 (fi) 2023-11-28
PT3798222T (pt) 2024-01-22
EP3328867B1 (en) 2020-11-11
MX2021002220A (es) 2022-09-01
HUE065536T2 (hu) 2024-05-28
TWI616449B (zh) 2018-03-01
CY1123689T1 (el) 2022-03-24
DK3328867T3 (da) 2020-11-16
US10420749B2 (en) 2019-09-24
US11020376B2 (en) 2021-06-01
CN116063322A (zh) 2023-05-05
EP3798222B1 (en) 2023-11-22
AU2016304420B2 (en) 2019-09-19
HK1252845A1 (zh) 2019-06-06
EP3328867A1 (en) 2018-06-06
TW201718600A (zh) 2017-06-01
EP3328867B9 (en) 2021-04-14
PL3798222T3 (pl) 2024-03-25
DK3798222T3 (da) 2023-12-11
PL3328867T3 (pl) 2021-04-19
WO2017021823A1 (en) 2017-02-09
JP6218253B2 (ja) 2017-10-25
RU2018101363A3 (sl) 2019-08-29
SG10201913200XA (en) 2020-03-30
EP3798222A1 (en) 2021-03-31
KR20180022936A (ko) 2018-03-06
CA2937257A1 (en) 2017-01-31
CN116063323A (zh) 2023-05-05
ES2972010T3 (es) 2024-06-10
JP2017039702A (ja) 2017-02-23
US20180235933A1 (en) 2018-08-23
ES2842302T3 (es) 2021-07-13
SI3798222T1 (sl) 2024-02-29
RU2018101363A (ru) 2019-08-29

Similar Documents

Publication Publication Date Title
IL288519B1 (en) inhibitors of ret
HK1252845A1 (zh) 勞拉替尼游離碱的結晶形式
SG11201706729SA (en) Derivatives of sobetirome
IL257026A (en) Solid state forms of eluxadoline
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
HK1244274A1 (zh) C21h22ci2n4o2的晶型
HK1250719A1 (zh) 脫氧糖胺的合成
ZA201706282B (en) Solid forms of menaquinols
PT3113773T (pt) Formas cristalinas do grapiprant
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL253479A0 (en) Crystalline forms of efinconazole
HUE057772T2 (hu) Kristályos formák
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
HK1255148A1 (zh) 結晶形式
GB201518589D0 (en) Crystalline form of tetraacetylethylenediamine
HUP1500506A2 (en) Salts of palbociclib
IL270937A (en) Crystalline forms of saltalicib
IL261795A (en) Crystalline form
GB201502834D0 (en) Composition of objects
HUP1400294A2 (hu) Clopidogrel új alkalmazása